首页> 外文期刊>Central European Journal of Urology: The Polish Journal of Urology >Successful treatment of locally advanced urachal adenocarcinoma with peri-operative gemcitabine –cisplatin combination therapy: a case report andperspective on targeted therapies
【24h】

Successful treatment of locally advanced urachal adenocarcinoma with peri-operative gemcitabine –cisplatin combination therapy: a case report andperspective on targeted therapies

机译:脑梗塞吉西他滨的局部晚期Urachal腺癌的成功治疗 - Clisplatin组合治疗:案例报告探讨有针对性疗法

获取原文
           

摘要

Urachal adenocarcinoma is a rare cancer and is treated based on the experience from case series and expert opinion as no randomized studies have been performed. This report adds to the current literature the experience of a patient with locally advanced urachal adenocarcinoma who was treated with combination of neoadjuvant gemcitabine/ cisplatin chemotherapy, surgery and adjuvant chemotherapy and has obtained a long recurrence free survival currently for more than 5 years. Although 5-FU-based chemotherapy is favored by many experts in the treatment of metastatic urachal adenocarcinoma, gemcitabine-based regimens have produced partial responses in metastatic disease and have been used in peri-operative treatment with a manageable adverse effect profile. A brief discussion of molecular lesions in urachal carcinomas and of the emerging role of targeted therapies is included in the current report.
机译:Urachal腺癌是一种罕见的癌症,并根据案例系列和专家意见的经验而治疗,因为没有进行随机研究。本报告增加了当前文献,患者具有局部晚期铀腺癌的经验,该患者被尼辅吉西他汀/顺铂化疗,手术和佐剂化疗的组合治疗,并在目前获得了长期的自由生存率超过5年。虽然许多基于5-fu的化疗在治疗转移性癌腺癌治疗中受到青睐,但基于吉西咪滨的方案在转移性疾病中产生了部分反应,并且已在具有可管理的不利影响概况的PERI-Imperative治疗中使用。本报告中介绍了王子癌中的分子病变和靶向治疗的新兴作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号